Breast Cancer Res. 2005;7(4):143-8. Epub 2005 May 5.

Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer.

Gusterson BA, Ross DT, Heath VJ, Stein T.

Source

Division of Cancer Sciences and Molecular Pathology, Western Infirmary, University of Glasgow, Glasgow, UK. bag5f@clinmed.gla.ac.uk

Abstract

Recent publications have classified breast cancers on the basis of expression of cytokeratin-5 and -17 at the RNA and protein levels, and demonstrated the importance of these markers in defining sporadic tumours with bad prognosis and an association with BRCA1-related breast cancers. These important observations using different technology platforms produce a new functional classification of breast carcinoma. However, it is important in developing hypotheses about the pathogenesis of this tumour type to review the nomenclature that is being used to emphasize potential confusion between terminology that defines clinical subgroups and markers of cell lineage. This article reviews the lineages in the normal breast in relation to what have become known as the 'basal-like' carcinomas.

PMID:: 15987465; [PubMed - indexed for MEDLINE]
PMCID:: PMC1175069

Free PMC Article

Images from this publication.See all images (1) Free text

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

Keratins

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Breast Cancer - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

Review Basal carcinoma of the breast revisited: an old entity with new interpretations. [J Clin Pathol. 2008]
Review Basal carcinoma of the breast revisited: an old entity with new interpretations.
Korsching E, Jeffrey SS, Meinerz W, Decker T, Boecker W, Buerger H. J Clin Pathol. 2008 May; 61(5):553-60. Epub 2008 Mar 6.
Do 'basal-like' breast cancers really exist? [Nat Rev Cancer. 2009]
Do 'basal-like' breast cancers really exist?
Gusterson B. Nat Rev Cancer. 2009 Feb; 9(2):128-34. Epub 2008 Dec 29.
Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2. [Pol J Pathol. 2005]
Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
Kusińska R, Potemski P, Jesionek-Kupnicka D, Kordek R. Pol J Pathol. 2005; 56(3):107-10.
The majority of triple-negative breast cancer may correspond to basal-like carcinoma, but triple-negative breast cancer is not identical to basal-like carcinoma. [Med Mol Morphol. 2009]
The majority of triple-negative breast cancer may correspond to basal-like carcinoma, but triple-negative breast cancer is not identical to basal-like carcinoma.
Kuroda N, Ohara M, Inoue K, Mizuno K, Fujishima N, Hamaguchi N, Lee GH. Med Mol Morphol. 2009 Jun; 42(2):128-31. Epub 2009 Jun 18.
Review Basal-like breast cancer and the BRCA1 phenotype. [Oncogene. 2006]
Review Basal-like breast cancer and the BRCA1 phenotype.
Turner NC, Reis-Filho JS. Oncogene. 2006 Sep 25; 25(43):5846-53.

See reviews... See all...

Cited by 23 PubMed Central articles

Review Basal breast cancer: a complex and deadly molecular subtype. [Curr Mol Med. 2012]
Review Basal breast cancer: a complex and deadly molecular subtype.
Bertucci F, Finetti P, Birnbaum D. Curr Mol Med. 2012 Jan; 12(1):96-110.
Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool? [BMC Cancer. 2011]
Nottingham Prognostic Index in triple-negative breast cancer: a reliable prognostic tool?
Albergaria A, Ricardo S, Milanezi F, Carneiro V, Amendoeira I, Vieira D, Cameselle-Teijeiro J, Schmitt F. BMC Cancer. 2011 Jul 15; 11:299. Epub 2011 Jul 15.
Basal-like phenotype in a breast carcinoma case series from Sudan: prevalence and clinical/pathological correlations. [Patholog Res Int. 2011]
Basal-like phenotype in a breast carcinoma case series from Sudan: prevalence and clinical/pathological correlations.
Awadelkarim KD, Arizzi C, Elamin EO, Hamad HM, De Blasio P, Mekki SO, Osman I, Biunno I, Elwali NE, Barberis MC, et al. Patholog Res Int. 2011 Jan 9; 2011:806831. Epub 2011 Jan 9.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
References for this PMC Article
Citation referenced in PubMed article. Only valid for PubMed citations that are also in PMC.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Free in PMC
Free full text articles in PMC
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Basal cytokeratins and their relationship to the cellular origin and functional ...
Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer.
Breast Cancer Res. 2005 ;7(4):143-8. Epub 2005 May 5 .

PubMed
The AIB1 glutamine repeat polymorphism is not associated with risk of breast can...
The AIB1 glutamine repeat polymorphism is not associated with risk of breast cancer before age 40 years in Australian women.
Breast Cancer Res. 2005 ;7(3):R353-6. Epub 2005 Mar 4 .

PubMed
Combining lectin microcolumns with high-resolution separation techniques for enr...
Combining lectin microcolumns with high-resolution separation techniques for enrichment of glycoproteins and glycopeptides.
Anal Chem. 2005 Jul 1 ;77(13):4081-90.

PubMed
A cross-national comparison of school drug policies in Washington State, United ...
A cross-national comparison of school drug policies in Washington State, United States, and Victoria, Australia.
J Sch Health. 2005 Apr ;75(4):134-40.

PubMed
Stem cell factor (SCF) and interleukin 3 (IL-3) in the sera of patients with col...
Stem cell factor (SCF) and interleukin 3 (IL-3) in the sera of patients with colorectal cancer.
Dig Dis Sci. 2005 Jun ;50(6):1019-24.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: